Table 2.
Demographic and clinical data.
| Characteristics | Results (n = 25) |
|---|---|
| Age (y) | 66 ± 9 (50 to 79) |
| Sex (F/M), n (%) | 5/20 (20/80) |
| Weight (kg) | 89 ± 21 (58 to 152) |
| Height (cm) | 178 ± 12 (156 to 198) |
| BMI (kg/m2) | 28 ± 5 (19 to 42) |
| Race, n (%) | |
| White | 24 (96) |
| Native Hawaiian or other Pacific Islander | 1 (4) |
| COVID-19, n (%) | 20 (80) |
| Indication for therapeutic dose nadroparin, n (%) | |
| DVT | 4 (16) |
| PE | 13 (52) |
| SPAF | 8 (32) |
| Serum creatinine (μmol/L) | 97 ± 63 (40 to 283) |
| eGFR (ml/min/1.73 m2) | 79 ± 29 (16 to 113) |
| CCr (mL/min) | 105 ± 51 (15 to 201) |
| CCr ≥ 50 (n = 22) | 115 ± 45 (51 to 201) |
| CCr ≥ 30 to 49 (n = 1) | 44 |
| CCr < 30 (n = 2) | 20 ± 6 (15 to 24) |
| APACHE IV score | 69 ± 18 (11 to 94) |
| SOFA score | 4 ± 2 (0 to 8) |
| Daily dosage per bodyweight (IU/kg/d) | 177 ± 34 (96 to 217) |
| CCr ≥ 50 (n = 22) | 180 ± 31 (96 to 217) |
| CCr ≥ 30 to 49 (n = 1) | 190 |
| CCr < 30 (n = 2) | 143 ± 63 (98 to 188) |
| Daily dosage per LBW (IU/kg/d) | 254 ± 58 (144 to 401) |
| CCr ≥ 50 (n = 22) | 257 ± 57 (144 to 401) |
| CCr ≥ 30 to 49 (n = 1) | 297 |
| CCr < 30 (n = 2) | 200 ± 64 (155 to 245) |
| Daily dosage per IBW (IU/kg/d) | 218 ± 54 (104 to 362) |
| CCr ≥ 50 (n = 22) | 224 ± 53 (104 to 362) |
| CCr ≥ 30 to 49 (n = 1) | 217 |
| CCr < 30 (n = 2) | 160 ± 60 (117 to 202) |
| No. of (identical) administrations (n) | 10 ± 5 (4 to 25) |
| Invasive mechanical ventilation, n (%) | 18 (72) |
| Vasopressor, n (%) | 5 (20) |
| CRP (mg/L) | 63 ± 62 (1 to 219) |
| Antithrombin (%) | 115 ± 19 (88 to 156)a |
| Heart failure, history of | |
| NYHA I | 18 (72) |
| NYHA II | 6 (24) |
| NYHA III | 1 (4) |
| Fluid balance (mL) | −105 ± 965 (−1711 to 2169) |
| Site of injection, n (%) | |
| Thigh | 13 (52) |
| Abdomen | 11 (44) |
| Unknown | 1 (4) |
Values are expressed as the mean ± SD (range), unless stated otherwise. Twice-daily 86-IE/kg nadroparin was considered as the unadjusted standard dosage (100%). IBWfemale = 45.5 kg + 0.91 kg × (height in centimeters − 152.4); IBWmale = 50 kg + 0.91 kg × (height in centimeters −152.4). LBWfemale= (9270 × weight in kilograms)/(8780 + [244 × BMI]); LBWmale = (9270 × weight in kilograms)/(6680 + [216 × BMI]).
APACHE IV, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; CCr, creatinine clearance (urine creatinine); CRP, C-reactive protein; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration in mL/min/1.73 m2); F, female; IBW, ideal body weight; LBW, lean body weight; M, male; NYHA, New York Heart Association; SOFA, Sequential Organ Failure Assessment; SPAF, stroke prevention in atrial fibrillation; PE, pulmonary embolism.
One missing data point, n = 24.